Magliozzi Patrizio, Strianese Diego, Bonavolontà Paola, Ferrara Mariantonia, Ruggiero Pasquale, Carandente Raffaella, Bonavolontà Giulio, Tranfa Fausto
Department of Neuroscience, Odontostomatological and Reproductive Sciences, University of Naples Federico II, Naples 80131, Italy.
Int J Ophthalmol. 2015 Oct 18;8(5):1018-23. doi: 10.3980/j.issn.2222-3959.2015.05.30. eCollection 2015.
To describe a series of Italian patients with orbital metastasis focusing on the outcomes in relation to the different primary site of malignancy.
Retrospective chart review of 93 patients with orbital metastasis collected in a tertiary referral centre in a period of 38y and review of literature.
Out of 93 patients, 52 were females and 41 were males. Median age at diagnosis was 51y (range 1 to 88y). The patients have been divided into four groups on the basis of the year of diagnosis. The frequency of recorded cases had decreased significantly (P<0.05) during the last 9.5y. Primary tumor site was breast in 36 cases (39%), kidney in 10 (11%), lung in 8 (9%), skin in 6 (6%); other sites were less frequent. In 16 case (17%) the primary tumor remained unknown. The most frequent clinical findings were proptosis (73%), limited ocular motility (55%), blepharoptosis (46%) and blurred vision (43%). The diagnosis were established by history, ocular and systemic evaluation, orbital imaging studies and open biopsy or fine needle aspiration biopsy (FNAB). Treatment included surgical excision, irradiation, chemotherapy, hormone therapy, or observation. Ninety-one percent of patients died of metastasis with an overall mean survival time (OMST) after the orbital diagnosis of 13.5mo.
Breast, kidney and lung are the most frequent primary sites of cancer leading to an orbital metastasis. When the primary site is unknown, gastrointestinal tract should be carefully investigated. In the last decade a decrease in the frequency of orbital metastasis has been observed. Surgery provides a local palliation. Prognosis remains poor with a OMST of 13.5mo ranging from the 3mo in the lung cancer to 24mo in the kidney tumor.
描述一系列意大利眼眶转移瘤患者,重点关注与不同恶性肿瘤原发部位相关的结局。
对一家三级转诊中心在38年期间收集的93例眼眶转移瘤患者进行回顾性病历审查,并查阅文献。
93例患者中,女性52例,男性41例。诊断时的中位年龄为51岁(范围1至88岁)。根据诊断年份,患者被分为四组。在过去9.5年中,记录病例的频率显著下降(P<0.05)。原发肿瘤部位为乳腺癌36例(39%),肾癌10例(11%),肺癌8例(9%),皮肤癌6例(6%);其他部位较少见。16例(17%)患者的原发肿瘤仍不明。最常见的临床表现为眼球突出(73%)、眼球运动受限(55%)、上睑下垂(46%)和视力模糊(43%)。通过病史、眼部和全身评估、眼眶影像学检查以及开放活检或细针穿刺活检(FNAB)确诊。治疗包括手术切除、放疗、化疗、激素治疗或观察。91%的患者死于转移,眼眶诊断后的总体平均生存时间(OMST)为13.5个月。
乳腺癌、肾癌和肺癌是导致眼眶转移的最常见原发癌部位。当原发部位不明时,应仔细检查胃肠道。在过去十年中,已观察到眼眶转移频率下降。手术可提供局部姑息治疗。预后仍然很差,OMST为13.5个月,肺癌患者为3个月,肾肿瘤患者为24个月。